A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia

Exclusion Criteria

• •1. Subjects with hypercalcaemia at screening
• •2. Subjects with intact parathyroid hormone (iPTH) levels \>700 pg/mL at screening.
• •3. Subjects who are PB naïve who weigh \<5 kg at screening. Subjects receiving stable doses of PBs who weigh \<6 kg at screening
• •4. Subjects requiring feeding tube sizes ≤6 FR (French catheter scale).
• •5. Subjects with history of major gastrointestinal surgery or significant gastrointestinal disorders.
• •6. Subjects with hypocalcaemia (serum total corrected calcium \<1.9 mmol/L; \<7.6 mg/dL) at screening.
• •7. Subject is pregnant (e.g., positive human chorionic gonadotropin test) or breast feeding.
• •8. Subject has a significant medical condition(s)